Insight Inv LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Insight Inv LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,739 shares of the company’s stock after selling 70 shares during the quarter. Insight Inv LLC’s holdings in Johnson & Johnson were worth $1,740,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Greenwood Gearhart Inc. boosted its holdings in shares of Johnson & Johnson by 9.8% in the third quarter. Greenwood Gearhart Inc. now owns 78,814 shares of the company’s stock valued at $12,772,000 after acquiring an additional 7,033 shares in the last quarter. Prestige Wealth Management Group LLC lifted its position in Johnson & Johnson by 0.4% in the third quarter. Prestige Wealth Management Group LLC now owns 26,607 shares of the company’s stock valued at $4,312,000 after purchasing an additional 116 shares during the period. Brophy Wealth Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $944,000. High Falls Advisors Inc lifted its holdings in shares of Johnson & Johnson by 15.7% in the 3rd quarter. High Falls Advisors Inc now owns 2,186 shares of the company’s stock valued at $354,000 after buying an additional 296 shares during the period. Finally, Conway Capital Management Inc. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $255,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $175.67.

Johnson & Johnson Price Performance

JNJ opened at $149.61 on Tuesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company’s 50 day simple moving average is $157.84 and its 200 day simple moving average is $156.40. The stock has a market capitalization of $360.20 billion, a PE ratio of 21.65, a P/E/G ratio of 2.65 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the business earned $2.66 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.